Atopic Dermatitis Drugs Market

Atopic Dermatitis Drugs Market (Product Type: Biologics and Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Atopic Dermatitis Drugs Maket Outlook 2031

  • The global industry was valued at US$ 11.5 Bn in 2022
  • It is projected to grow at a CAGR of 8.9% from 2023 to 2031 and reach more than US$ 28.2 Bn by the end of 2031

Analysts’ Viewpoint

Rise in prevalence of atopic dermatitis is driving the global atopic dermatitis drugs market. Prevalence of atopic dermatitis has been increasing, with a significant rise in both adults and children. Introduction of innovative therapies and treatment options for atopic dermatitis are expected to propel market expansion. Furthermore, increase in demand for biologics, rise in new product approvals, and surge in healthcare expenditure, especially in developing countries, are likely to bolster the global atopic dermatitis drugs market size during the forecast period.

Development of effective and targeted therapies for atopic dermatitis offers lucrative opportunities to market players. Leading companies are focusing on improving access to healthcare services and providing affordable treatments such as targeted biologic therapies and topical medications in order to increase market share.

Atopic Dermatitis Drugs Market

Global Atopic Dermatitis Drugs Market Introduction

Atopic dermatitis is a skin condition that causes dry, itchy, and inflamed skin. It is most common in young children, but it could happen at any age. Atopic dermatitis is a chronic condition that flares up from time to time. It can be annoying, but it is not contagious.

Atopic dermatitis is a common disease that typically manifests itself during infancy and childhood. Several children's atopic dermatitis resolves before adolescence. Some children with atopic dermatitis may continue to have symptoms as teenagers and adults. In some cases, the disease manifests itself during adulthood.

Atopic dermatitis has shown positive response to biologic therapies. These therapies have improved the overall quality of life. Hence, demand for biologic drugs for atopic dermatitis has increased significantly, and the trend is likely to continue in the next few years.

High Prevalence of Atopic Dermatitis Fueling Market Development

Dermatological disorders differ across the globe based on geographic location, climatic conditions, socioeconomic status, lifestyles, age, gender, heredity, and personal habits. High prevalence of atopic dermatitis across the globe is a major factor driving the atopic dermatitis drugs market growth.

According to the World Health Organization (WHO), over 900 million people were affected with skin disease in 2017, and around 80% of the skin disorders are accounted for by the five common skin disorders. Atopic dermatitis, a common and chronic inflammatory skin disease, affects 15% to 20% of children and 1% to 3% of adults across the world.

In 2022, atopic dermatitis affected 223 million people globally, of these 43 million were children under the age of five. Atopic dermatitis can have a negative impact on children’s development and schooling.

The condition is not common everywhere. According to the 2017 Global Burden of Disease (GBD) data, Sweden, the U.K., Iceland, Finland, and Denmark had the five highest scores, while Uzbekistan, Armenia, Tajikistan, China, and Kazakhstan had the five lowest scores. Hence, rise in incidence of atopic dermatitis across the globe and increase in awareness about the disease are projected to drive the atopic dermatitis drugs market demand during the forecast period.

Better Clinical Outcomes and Quality of Life Bolstering Demand for Biologics

In terms of product type, the biologics segment accounted for the largest global atopic dermatitis drugs market share in 2022. This is ascribed to increase in the number of biologic drug approvals in the past few years. Biologics are considered to represent a breakthrough in the management of atopic dermatitis because of the improvement seen in clinical outcomes and the quality of life of patients.

Biologics work differently than other atopic dermatitis treatments. Instead of treating general inflammation all over the body, they target specific molecules and do not go through the whole system. Hence, they tend to cause fewer side effects than other treatments. This is propelling the biologics segment.

Recent approvals and launches, such as Abbvie’s Rinvoq, Pfizer’s Cibinqo, and Incyte’s Opzelura, indicate that demand for biologic drugs in the treatment of atopic dermatitis is rising across the globe, especially in the U.S. and Europe, where large populations are affected.

Availability of Treatments for Atopic Dermatitis in Hospital Pharmacies

Based on distribution channel, the hospital pharmacies segment dominated the global atopic dermatitis drugs market in 2022. Distribution channels for atopic dermatitis, including biologics, can vary depending on the region and healthcare system.

Atopic dermatitis can be treated with a range of medications, including topical corticosteroids, immunomodulators, emollients, and biologics. These medications are largely available at hospital pharmacies. Hence, the hospital pharmacies segment dominated the global atopic dermatitis drugs market in 2022.

Regional Outlook

Atopic dermatitis is relatively common in North America, with a significant number of individuals affected by the condition. This high prevalence drives demand for effective treatments and contributes to the expansion of the market.

As per atopic dermatitis drugs market research, the U.S. is likely to dominate the industry during the forecast period owing to its large patient population and usage of biologic drugs in the affected population of patients with atopic dermatitis.

According to the National Eczema Association, around 9.6 million U.S. children under the age of 18 have atopic dermatitis, and one-third have moderate-to-severe disease. An estimated 16.5 million U.S. adults (7.3%) have atopic dermatitis, with nearly 40% affected by moderate-to-severe disease.

North America boasts a well-developed healthcare infrastructure, including hospitals, specialized dermatology clinics, research institutions, and pharmaceutical companies. This infrastructure supports the diagnosis, treatment, and development of new therapies for atopic dermatitis.

Analysis of Key Players

The global atopic dermatitis drugs market is consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are the key strategies implemented by the leading players in the global industry.

Sanofi, Pfizer, AbbVie, Leo Pharma, Eli Lilly, Teva Pharmaceutical Industries Ltd., and Novartis AG are the prominent players in the global atopic dermatitis drugs market.

Key Developments in Global Atopic Dermatitis Drugs Market

  • In October 2022, LEO Pharma announced that the European Commission (EC) extended the marketing authorization for Adtralza (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
  • In August 2021, the European Commission (EC) approved RINVOQ (upadacitinib) as the first JAK inhibitor in the European Union for the treatment of both adults and adolescents with moderate to severe atopic dermatitis. The approval was based on the results of two phase 3 clinical trials, which showed that RINVOQ was effective at reducing the signs and symptoms of atopic dermatitis, including itching, redness, swelling, and oozing.

Each of these players has been profiled in the atopic dermatitis drugs market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Atopic Dermatitis Drugs Market Snapshot

Attribute Detail
Size in 2022 US$ 11.5 Bn
Market Forecast Value in 2031 More than US$ 28.2 Bn
Growth Rate (CAGR) 8.9%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Product Type
    • Biologics
    • Others
  • Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries
Companies Profiled
  • Sanofi
  • Pfizer
  • AbbVie
  • LEO Pharma A/S
  • Eli Lilly
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global atopic dermatitis drugs market in 2022?

It was valued at US$ 11.5 Bn in 2021

How big will the atopic dermatitis drugs industry be in 2031?

It is projected to reach more than US$ 28.2 Bn by 2031

What will be the CAGR of the atopic dermatitis drugs business during the forecast period (2023-2031)?

The CAGR is anticipated to be 8.9% from 2023 to 2031

What are key factors driving demand for atopic dermatitis drugs?

Rise in prevalence of atopic dermatitis and increase in demand for biologics and new product approvals

Which region is expected to hold major share of the global atopic dermatitis drugs sector during the forecast period?

North America is likely to account for significant share during the forecast period

Who are the prominent atopic dermatitis drug manufacturers?

Sanofi, Pfizer, AbbVie, Leo Pharma, Eli Lilly, Teva Pharmaceutical Industries Ltd, and Novartis AG

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Atopic Dermatitis Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Disease Prevalence Assessment, by Eczema

        5.3. Key Industry Events (Mergers & Acquisitions, Partnerships, Product Launches, etc.)

        5.4. COVID-19 Impact Analysis

    6. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Product Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Product Type, 2017-2031

            6.3.1. Biologics

            6.3.2. Others

        6.4. Market Attractiveness, by Product Type

    7. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Distribution Channel

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Distribution Channel, 2017-2031

            7.3.1. Hospital Pharmacies

            7.3.2. Retail Pharmacies

            7.3.3. Online Pharmacies

        7.4. Market Attractiveness, by Distribution Channel

    8. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness, by Region

    9. North America Atopic Dermatitis Drugs Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Product Type, 2017-2031

            9.2.1. Biologics

            9.2.2. Others

        9.3. Market Value Forecast, by Distribution Channel, 2017-2031

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. Market Value Forecast, by Country, 2017-2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Product Type

            9.5.2. By Distribution Channel

            9.5.3. By Country

    10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Product Type, 2017-2031

            10.2.1. Biologics

            10.2.2. Others

        10.3. Market Value Forecast, by Distribution Channel, 2017-2031

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. Online Pharmacies

        10.4. Market Value Forecast, by Country/Sub-region, 2017-2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Product Type

            10.5.2. By Distribution Channel

            10.5.3. By Country/Sub-region

    11. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product Type, 2017-2031

            11.2.1. Biologics

            11.2.2. Others

        11.3. Market Value Forecast, by Distribution Channel, 2017-2031

            11.3.1. Hospital Pharmacies

            11.3.2. Retail Pharmacies

            11.3.3. Online Pharmacies

        11.4. Market Value Forecast, by Country/Sub-region, 2017-2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Product Type

            11.5.2. By Distribution Channel

            11.5.3. By Country/Sub-region

    12. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product Type, 2017-2031

            12.2.1. Biologics

            12.2.2. Others

        12.3. Market Value Forecast, by Distribution Channel, 2017-2031

            12.3.1. Hospital Pharmacies

            12.3.2. Retail Pharmacies

            12.3.3. Online Pharmacies

        12.4. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Product Type

            12.5.2. By Distribution Channel

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product Type, 2017-2031

            13.2.1. Biologics

            13.2.2. Others

        13.3. Market Value Forecast, by Distribution Channel, 2017-2031

            13.3.1. Hospital Pharmacies

            13.3.2. Retail Pharmacies

            13.3.3. Online Pharmacies

        13.4. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Product Type

            13.5.2. By Distribution Channel

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competitive Matrix (by tier and size of companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Sanofi

                14.3.1.1. Company Overview

                14.3.1.2. Product Portfolio

                14.3.1.3. Financial Overview

                14.3.1.4. Strategic Overview

                14.3.1.5. SWOT Analysis

            14.3.2. Pfizer

                14.3.2.1. Company Overview

                14.3.2.2. Product Portfolio

                14.3.2.3. Financial Overview

                14.3.2.4. Strategic Overview

                14.3.2.5. SWOT Analysis

            14.3.3. AbbVie

                14.3.3.1. Company Overview

                14.3.3.2. Product Portfolio

                14.3.3.3. Financial Overview

                14.3.3.4. Strategic Overview

                14.3.3.5. SWOT Analysis

            14.3.4. Leo Pharma

                14.3.4.1. Company Overview

                14.3.4.2. Product Portfolio

                14.3.4.3. Financial Overview

                14.3.4.4. Strategic Overview

                14.3.4.5. SWOT Analysis

            14.3.5. Eli Lilly and Company

                14.3.5.1. Company Overview

                14.3.5.2. Product Portfolio

                14.3.5.3. Financial Overview

                14.3.5.4. Strategic Overview

                14.3.5.5. SWOT Analysis

            14.3.6. Novartis AG

                14.3.6.1. Company Overview

                14.3.6.2. Product Portfolio

                14.3.6.3. Financial Overview

                14.3.6.4. Strategic Overview

                14.3.6.5. SWOT Analysis

            14.3.7. Teva Pharmaceutical Industries Ltd.

                14.3.7.1. Company Overview

                14.3.7.2. Product Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. Strategic Overview

                14.3.7.5. SWOT Analysis

    List of Tables

    Table 01: Global Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

    Table 02: Global Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 03: Global Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031

    Table 04: North America Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031

    Table 05: North America Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

    Table 06: North America Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 07: Europe Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 08: Europe Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

    Table 09: Europe Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 10: Asia Pacific Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 11: Asia Pacific Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

    Table 12: Asia Pacific Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 13: Latin America Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 14: Latin America Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

    Table 15: Latin America Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 16: Middle East & Africa Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 17: Middle East & Africa Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

    Table 18: Middle East & Africa Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    List of Figures

    Figure 01: Global Atopic Dermatitis Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031

    Figure 02: Global Atopic Dermatitis Drugs Market Revenue (US$ Mn), by Product Type, 2021

    Figure 03: Global Atopic Dermatitis Drugs Market Value Share, by Product Type, 2021

    Figure 04: Global Atopic Dermatitis Drugs Market Revenue (US$ Mn), by Distribution Channel, 2021

    Figure 05: Global Atopic Dermatitis Drugs Market Value Share, by Distribution Channel, 2021

    Figure 06: Global Atopic Dermatitis Drugs Market Value Share, by Region, 2021

    Figure 07: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017-2031

    Figure 08: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Product Type, 2017 and 2031

    Figure 09: Global Atopic Dermatitis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Biologics, 2017-2031

    Figure 10: Global Atopic Dermatitis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031

    Figure 11: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Product Type, 2022-2031

    Figure 12: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 13: Global Atopic Dermatitis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2031

    Figure 14: Global Atopic Dermatitis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2031

    Figure 15: Global Atopic Dermatitis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017-2031

    Figure 16: Global Atopic Dermatitis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031

    Figure 17: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031

    Figure 18: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Region, 2017 and 2031

    Figure 19: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Region, 2022-2031

    Figure 20: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 21: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country, 2017-2031

    Figure 22: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Country, 2017 and 2031

    Figure 23: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Product Type, 2017 and 2031

    Figure 24: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 25: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Product Type, 2022-2031

    Figure 26: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031

    Figure 27: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 28: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 29: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 30: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Product Type, 2017 and 2031

    Figure 31: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 32: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Product Type, 2022-2031

    Figure 33: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031

    Figure 34: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 35: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 36: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 37: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Product Type, 2017 and 2031

    Figure 38: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 39: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Product Type, 2022-2031

    Figure 40: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031

    Figure 41: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 42: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 43: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 44: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Product Type, 2017 and 2031

    Figure 45: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 46: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Product Type, 2022-2031

    Figure 47: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031

    Figure 48: Middle East & Africa Atopic Dermatitis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 49: Middle East & Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 50: Middle East & Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 51: Middle East & Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Product Type, 2017 and 2031

    Figure 52: Middle East & Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 53: Middle East & Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Product Type, 2022-2031

    Figure 54: Middle East & Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031

Copyright © Transparency Market Research, Inc. All Rights reserved